Avadel Pharmaceuticals PLC (AVDL NASDAQ) stock market data APIs
$21.816
0.02(0.1%)
as of February 11, 2026
Try our APIs with
free plan!
Avadel Pharmaceuticals PLC Financial Data Overview
Price chart is built with
Anychart
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Prev. Close
21.816
Open
21.836
High
21.8939
Low
21.4796
52 wk Range
6.38-23.57
Market Cap
2 124 M
P/E Ratio
0
Shares Outstanding
98 151 K
Revenue
249 M
EPS
0.0002
Beta
1.632
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Avadel Pharmaceuticals PLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Avadel Pharmaceuticals PLC data using free add-ons & libraries
Get Avadel Pharmaceuticals PLC Fundamental Data
Avadel Pharmaceuticals PLC Fundamental data includes:
- Net Revenue: 249 M
- EBITDA: 2 699 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: 0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Avadel Pharmaceuticals PLC News
New
Alkermes Completes Acquisition of Avadel
Alkermes (ALKS) completed its acquisition of Avadel Pharmaceuticals (AVDL) following the Irish High PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
— Augments Alkermes’ Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ® (Sodium Oxybate) for Extended-Release Oral Suspension — — Exp...
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing
Avadel Pharmaceuticals plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGUL...
BlackRock, Inc. (BLK) to Invest $333.6M in India’s Aditya Birla Renewables Limited
BlackRock Inc. (NYSE:BLK) is one of the best blue-chip stocks to buy for 2026. On January 6, reports emerged indicating BlackRock Inc. (NYSE:BLK) is seeking regulatory clearance in India to acquire an...
Get Avadel Pharmaceuticals PLC fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
